Weekly update Companies AI-cruiter Recruiting

Immunovant

Founded: 2018

Location: Durham, NC

Employee range: 50 - 200

Clinical stage: Clin3

Therapy area: Myasthenia gravis

Drug types: NEU, MUS, OPH, END, IMM

Lead product: IMVT-1401

Product link: https://www.immunovant.com/our-science/pipeline-and-therapeutic-areas

Funding: $75M stock Oct 2022

immunovant.com

linkedin.com

job board

Short description:

Monoclonal Antibody

Drug notes:

Also Clin3 thyroid eye disease, Clin2b inflammatory demyelinating polyneuropathy, Clin2 Graves disease; IMVT-1402 Clin0 autoimmune diseases

Long description:

Immunovant is creating therapies for autoimmune diseases. Autoimmune diseases arise when a patient's immune system incorrectly identifies healthy cells as harmful and thus generates autoantibodies. FcRn is a protein receptor that prevents degradation of autoantibodies. Immunovant’s lead product, IMVT-1401, is a human anti-FcRn monoclonal antibody that can be delivered via subcutaneous injection. IMVT-1401 inhibits and enhances degradation of FcRn, thereby allowing degradation of autoantibodies that cause autoimmune disease. Immunovant plans to test IMVT-1401 against a variety of indications, including thyroid eye disease and Myasthenia Gravis.